

ASCEND 5: LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

14/08/2025 23:13:35 Main Information Primary registry identifying number Protocol number LBCTR2019121371 CLDK378A2303 MOH registration number ص/9878 Study registered at the country of origin Study registered at the country of origin: Specify Type of registration Type of registration: Justify Retrospective This ongoing study was submitted before initiation of LBCTR Date of registration in national regulatory agency 10/11/2014 **Primary sponsor** Primary sponsor: Country of origin Novartis Pharmaceuticals **Novartis Pharmaceuticals** Date of registration in primary registry Date of registration in national regulatory agency 07/01/2020 10/11/2014 Public title Acronym ASCEND 5: LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Scientific title Acronym A Phase III, Multicenter, Randomized, Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients With ALK -rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer Who Have Been Treated Previously With Chemotherapy (Platinum Doublet) and Crizotinib Brief summary of the study: English The primary purpose of the study was to compare the antitumor activity of LDK378 vs. chemotherapy in patients previously treated with chemotherapy (platinum doublet) and crizotinib. Brief summary of the study: Arabic عن طريق الفم مقابل المعالجة الكيميائيّة العاديّة لدى مرضى LDK378 در اسة مرحلة ثالثة متعددة المراكز وجزافيّة ومفتوحة التسمية لدواء بالغين مصّابين بسُرطانَ الرئة غير ذي الخلايا الصغيرة المتقدّم، كينازَ الورّم اللّمفي الكشمي المعاد ترتيبه (كيناز الورّم اللمفي الكشمي الإيجابيّ) وخاضعين سابقًا للمعالجة الكيميانيّة (البلاتين المزدّوج) وللكريزوتينيب Health conditions/problem studied: Specify

Advanced non-small cell lung cancer (NSCLC)

Interventions: Specify

Drug: Ceritinib

Yes

Ceritinib is the investigational treatment and is referred to as the investigational study drug and was provided as 150 mg hard gelatin capsules for oral use. The dose was 750 mg once daily.



REPUBLIC OF LEBANON Lebanon Clinical Trials Registry MINISTRY OF PUBLIC HEALTH

Drug: pemetrexed

Pemetrexed was one of the chemotherapy treatments. Pemetrexed, a reconstituted solution, was intravenously administered over 10 minutes at 500 mg/m2 every 21 days.

Drug: docetaxel

Docetaxel was one of the chemotherapy treatments. Docetaxel, a reconstituted solution, was intravenously administered over 1 hour, at 75 mg/m2 every 21 days.

Key inclusion and exclusion criteria: Inclusion criteria

Inclusion Criteria

1.Patient has a histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive as assessed by the FDA approved Abbott FISH Test.

2.Patient has stage IIIB or IV diagnosis and must have received one or two prior regimens (including platinum- doublet) of cytotoxic chemotherapy for the treatment of locally advanced or metastatic NSCLC.

3. Patient has at least one measurable lesion as defined by RECIST 1.1. A previously irradiated site lesion may only be counted as a target lesion if there is clear sign of progression since the irradiation

4.Patients must have received previous treatment with crizotinib for the treatment of locally advanced or metastatic NSCLC.

Key inclusion and exclusion criteria: Gender Key inclusion and exclusion criteria: Specify gender Both Key inclusion and exclusion criteria: Age minimum Key inclusion and exclusion criteria: Age maximum 99

18

Key inclusion and exclusion criteria: Exclusion criteria

Exclusion Criteria:

1. Patient with known hypersensitivity to any of the excipients of LDK378 (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and magnesium stearate)

2.Patient with a history of severe hypersensitivity reaction to pemetrexed or docetaxel or any known excipients of these drugs. 3.Patient with symptomatic central nervous system (CNS) metastases who is neurologically unstable or has required increasing doses of

steroids within the 2 weeks prior to screening to manage CNS symptoms.

Type of study

Interventional

Type of intervention	Type of intervention: Specify type	
Pharmaceutical	N/A	
Trial scope	Trial scope: Specify scope	
Safety	N/A	
Study design: Allocation	Study design: Masking	
Randomized controlled trial	Open (masking not used)	
Study design: Control	Study phase	
Active	3	
Study design: Purpose	Study design: Specify purpose	
Treatment	N/A	
Study design: Assignment	Study design: Specify assignment	
Parallel	N/A	
IMP has market authorization	IMP has market authorization: Specify	
Yes, Worldwide	Argentina, Aruba, Australia, Austria, Belgium, Brunei, Canada, Chile, China, Costa Rica, Croatia, Curacao, Czech Republic, Denmark, Dominican Republic, El Salvador, Finland, France, Germany,	
Name of IMP	Year of authorization Month of authorization	
LDK378 (Ceritinib)		
Type of IMP		





REPUBLIC OF LEBANON Lebanon Clinical Trials Registry

Cell therapy

Pharmaceutical class

5-Chloro-2-N-{5-methyl-4-(piperidin-4-yl)-2-[(propan-2-yl)oxy]phenyl}-4-N-[2-(propane-2-sulfonyl) phenyl]pyrimidine-2,4-diamine

Therapeutic indication

This study will be conducted in adult male or female patients, with ALK-rearranged (as determined by the Abbott FISH test), advanced (Stage IIIB or IV) NSCLC, who have received previous treatment with cytotoxic chemotherapy (one or two prior regimens, including one platinum doublet) and crizotinib, and have demonstrated disease progression at study enrollment. No particular sequence of prior crizotinib and chemotherapy is required for enrollment, and either can comprise the last treatment received by the patient.

Therapeutic benefit

Progression Free Survival (PFS) and Overall Survival (OS)

Study model	Study model: Explain model
N/A	N/A
Study model: Specify model	
N/A	
Time perspective	Time perspective: Explain time perspective
N/A	N/A
Time perspective: Specify perspective	
N/A	
Target follow-up duration	Target follow-up duration: Unit
Number of groups/cohorts	
Bissussimen retention	Rissnasimen description
Biospecimen retention	Biospecimen description
None retained	NA
Target sample size	Actual aprollment target size
Target sample size	Actual enrollment target size
Target sample size 2	Actual enrollment target size
2	2
2 Date of first enrollment: Type Actual	2 Date of first enrollment: Date 28/01/2015
2 Date of first enrollment: Type	2 Date of first enrollment: Date
2 Date of first enrollment: Type Actual	2 Date of first enrollment: Date 28/01/2015
2 Date of first enrollment: Type Actual Date of study closure: Type Actual	2 Date of first enrollment: Date 28/01/2015 Date of study closure: Date 31/12/2020
2 Date of first enrollment: Type Actual Date of study closure: Type	2 Date of first enrollment: Date 28/01/2015 Date of study closure: Date



Date of completion

30/10/2015

IPD sharing statement plan

No

IPD sharing statement description

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Additional data URL

https://clinicaltrials.gov/ct2/show/record/NCT01828112?term=ldk378&cond=Lung+Cancer&cntry=LB&draw=1&rank=2

Admin comments

Trial status

Approved

Secondary Identifying Numbers	
Full name of issuing authority	Secondary identifying number
clinicaltrials.gov	NCT01828112

Sources of Monetary or Material Support

Name	
Novartis Pharmaceuticals	

Secondary Sponsors	
Name	
NA	

Contact for Public/Scientific Queries						
Contact type	Contact full name	Address	Country	Telephone	Email	Affiliation
Public	Marwan Ghosn	Beirut	Lebanon	03-226842	marwanghosnmd @yahoo.com	Hotel Dieu De France
Scientific	Hind Khairallah	Sin elfil	Lebanon	+961 1512002E xt. 271	Hind.Khairallah@ fattal.com.lb	Khalil Fattal et Fils s.a.l.

 \sim




Centers/Hospitals Involved in the Study			
Center/Hospital name Name of principles investigator Principles investigator speciality Ethical approval			
Hotel Dieu De France	Marwan Ghosn	Hematology oncology	Approved

Ethics Review				
Ethics approval obtained	Approval date	Contact name	Contact email	Contact phone
Hotel Dieu de France	22/10/2014	Nancy Alam	nancy.alam@usj.edu.lb	961 (0) 1 421000 ext 2335

Countries of Recruitment
Name
Lebanon
Belgium
France
Canada
Germany
Italy
Japan
Netherlands
Turkey
United Kingdom
United States of America

Health Conditions or Problems Studied

Condition	Code	Keyword
Advanced non-small cell lung cancer (NSCLC)	Bronchus or lung, unspecified (C34.9)	Advanced non-small cell lung cancer (NSCLC)





Interventions		
Intervention	Description	Keyword
ICF, physical assessment, ECG, radiology, PK sampling	ICF, physical assessment, ECG, radiology, PK sampling	ICF, physical assessment, ECG, radiology, PK sampling

Primary Outcomes		
Name	Time Points	Measure
Progression Free Survival (PFS)	24 months	24 months

Key Secondary Outcomes		
Name	Time Points	Measure
Overall Survival (OS)	18 months	18 months
Overall Response Rate (ORR) [18 months	18 months
Patient Reported Outcomes (PRO)	every 6 weeks	every 6 weeks



Trial Results Summary results Study results globally Date of posting of results summaries Date of posting of results summaries Date of first journal publication of results Results URL link Baseline characteristics Participant flow Adverse events Outcome measures URL to protocol files